Incremental benefit of high dose compared to standard dose influenza vaccine in reducing hospitalizations
Abstract Evidence regarding the high-dose (HD) vaccine’s relative vaccine effectiveness (rVE) and absolute benefit in reducing influenza-related hospitalizations compared to the standard-dose (SD) vaccine is warranted. We estimated the adjusted rVE and the number needed to vaccinate (NNV) of the HD...
Saved in:
| Main Authors: | , , , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Nature Portfolio
2025-01-01
|
| Series: | npj Vaccines |
| Online Access: | https://doi.org/10.1038/s41541-025-01065-5 |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
| _version_ | 1841544995253780480 |
|---|---|
| author | Shlomit Yaron Matan Yechezkel Dan Yamin Talish Razi Ilya Borochov Erez Shmueli Ronen Arbel Doron Netzer |
| author_facet | Shlomit Yaron Matan Yechezkel Dan Yamin Talish Razi Ilya Borochov Erez Shmueli Ronen Arbel Doron Netzer |
| author_sort | Shlomit Yaron |
| collection | DOAJ |
| description | Abstract Evidence regarding the high-dose (HD) vaccine’s relative vaccine effectiveness (rVE) and absolute benefit in reducing influenza-related hospitalizations compared to the standard-dose (SD) vaccine is warranted. We estimated the adjusted rVE and the number needed to vaccinate (NNV) of the HD vaccine compared to the SD vaccine among Clalit Health Services members aged ≥65 years. Among 418,603 and 393,125 members vaccinated in the 2022–2023 and 2023–2024 influenza seasons, the adjusted rVE was 27% (95% CI: −12% to 61%) for 2022–2023 and 7% (95% CI: −36% to 42%) for 2023–2024, with NNV to prevent one hospitalization event being 2262 (95% CI: 1004 to ∞) and 7662 (95% CI: 1293 to ∞), respectively. Even among the highest-risk subgroup, the NNV was 1289 (95% CI: 571 to ∞) for 2022–2023 and 4719 (95% CI: 797 to ∞) for 2023–2024. The HD vaccine exhibited a limited incremental benefit, even for individuals at the highest risk. |
| format | Article |
| id | doaj-art-b10ef6a4001e4db2977638151fb8b9ad |
| institution | Kabale University |
| issn | 2059-0105 |
| language | English |
| publishDate | 2025-01-01 |
| publisher | Nature Portfolio |
| record_format | Article |
| series | npj Vaccines |
| spelling | doaj-art-b10ef6a4001e4db2977638151fb8b9ad2025-01-12T12:07:12ZengNature Portfolionpj Vaccines2059-01052025-01-011011710.1038/s41541-025-01065-5Incremental benefit of high dose compared to standard dose influenza vaccine in reducing hospitalizationsShlomit Yaron0Matan Yechezkel1Dan Yamin2Talish Razi3Ilya Borochov4Erez Shmueli5Ronen Arbel6Doron Netzer7Schneider Children’s HospitalDepartment of Industrial Engineering, Tel Aviv UniversityDepartment of Industrial Engineering, Tel Aviv UniversityCommunity Medical Services Division, Clalit Health ServicesCommunity Medical Services Division, Clalit Health ServicesDepartment of Industrial Engineering, Tel Aviv UniversityCommunity Medical Services Division, Clalit Health ServicesCommunity Medical Services Division, Clalit Health ServicesAbstract Evidence regarding the high-dose (HD) vaccine’s relative vaccine effectiveness (rVE) and absolute benefit in reducing influenza-related hospitalizations compared to the standard-dose (SD) vaccine is warranted. We estimated the adjusted rVE and the number needed to vaccinate (NNV) of the HD vaccine compared to the SD vaccine among Clalit Health Services members aged ≥65 years. Among 418,603 and 393,125 members vaccinated in the 2022–2023 and 2023–2024 influenza seasons, the adjusted rVE was 27% (95% CI: −12% to 61%) for 2022–2023 and 7% (95% CI: −36% to 42%) for 2023–2024, with NNV to prevent one hospitalization event being 2262 (95% CI: 1004 to ∞) and 7662 (95% CI: 1293 to ∞), respectively. Even among the highest-risk subgroup, the NNV was 1289 (95% CI: 571 to ∞) for 2022–2023 and 4719 (95% CI: 797 to ∞) for 2023–2024. The HD vaccine exhibited a limited incremental benefit, even for individuals at the highest risk.https://doi.org/10.1038/s41541-025-01065-5 |
| spellingShingle | Shlomit Yaron Matan Yechezkel Dan Yamin Talish Razi Ilya Borochov Erez Shmueli Ronen Arbel Doron Netzer Incremental benefit of high dose compared to standard dose influenza vaccine in reducing hospitalizations npj Vaccines |
| title | Incremental benefit of high dose compared to standard dose influenza vaccine in reducing hospitalizations |
| title_full | Incremental benefit of high dose compared to standard dose influenza vaccine in reducing hospitalizations |
| title_fullStr | Incremental benefit of high dose compared to standard dose influenza vaccine in reducing hospitalizations |
| title_full_unstemmed | Incremental benefit of high dose compared to standard dose influenza vaccine in reducing hospitalizations |
| title_short | Incremental benefit of high dose compared to standard dose influenza vaccine in reducing hospitalizations |
| title_sort | incremental benefit of high dose compared to standard dose influenza vaccine in reducing hospitalizations |
| url | https://doi.org/10.1038/s41541-025-01065-5 |
| work_keys_str_mv | AT shlomityaron incrementalbenefitofhighdosecomparedtostandarddoseinfluenzavaccineinreducinghospitalizations AT matanyechezkel incrementalbenefitofhighdosecomparedtostandarddoseinfluenzavaccineinreducinghospitalizations AT danyamin incrementalbenefitofhighdosecomparedtostandarddoseinfluenzavaccineinreducinghospitalizations AT talishrazi incrementalbenefitofhighdosecomparedtostandarddoseinfluenzavaccineinreducinghospitalizations AT ilyaborochov incrementalbenefitofhighdosecomparedtostandarddoseinfluenzavaccineinreducinghospitalizations AT erezshmueli incrementalbenefitofhighdosecomparedtostandarddoseinfluenzavaccineinreducinghospitalizations AT ronenarbel incrementalbenefitofhighdosecomparedtostandarddoseinfluenzavaccineinreducinghospitalizations AT doronnetzer incrementalbenefitofhighdosecomparedtostandarddoseinfluenzavaccineinreducinghospitalizations |